{
  "docId": "019de070-3657-744f-8469-a4294fbedcbe",
  "docSlug": "17e3f38e05c3dcb59be9aebb9723e39c",
  "documentTitle": "Relay Therapeutics | IPO Presentation Deck | 25 slides",
  "authorId": "relay-therapeutics",
  "authorName": "Relay Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 25,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "The table highlights the limitations of current pan-FGFR inhibitors (Pemigatinib, Infigratinib, TAS-120, Erdafitinib) regarding hyperphosphatemia and discontinuation rates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3657-744f-8469-a4294fbedcbe/12",
  "deckHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe",
  "deckJsonHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe.json",
  "deckAnchorHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.2,
        "y": 0.82
      },
      "kind": "callout",
      "text": "An FGFR2-selective molecule could enable more complete and durable target inhibition, resulting in greater efficacy with reduced toxicity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ea994d1-0c6a-4a53-b531-b88b73f9efdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.7
      },
      "kind": "callout",
      "text": "Discontinuous dosing and high toxicity limits efficacy of non-selective FGFR inhibitors",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b727cc35-d99c-4a3e-91a7-6de5c60fca85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Sources: Pemigatinib – ESMO 2019; Infigratinib – BridgeBio S-1; TAS-120 – ASCO 2020 Presentation of Interim Analysis; Erdafitinib – Prescribing information; N.R. – not reported",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9efc0f95-0ea4-4a8e-a288-91cbad3c3095",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "table",
      "text": "Compound, Company, Stage, FGFR2 selective, Response Rate, Dosing Schedule, % of Patients with Hyperphosphatemia, % of Patients Discontinued or Dose Reduced",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b60d55c7-7c91-4664-9dfa-4777f54a5e66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "FGFR2 – Selective Inhibitor Required to Overcome Pan-FGFRi Limitations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3974a451-7200-44b4-bb80-9dd26f803cce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "d41eacd4-58f5-4546-a249-919344493707",
      "evidence": "Table comparing competitive compounds across key performance metrics to highlight a market gap.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 12,
      "beatId": "2cf08f78-192d-43a4-9440-c2c7cf6c1686",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Competitive Analysis",
      "beatSlug": "sequoia-pitch-competition",
      "evidence": "Competitive analysis is presented on slide 12",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}